Study Stopped
Expired with UF IRB.
Observational Study of Biomarker During Liver Surgery
Autophagy in Liver Injury: Changes in Autophagy Biomarkers During Liver Surgery
2 other identifiers
observational
41
1 country
1
Brief Summary
The investigators would like to study whether Sirtuin 1 (SIRT1) plays a cytoprotective role in liver ischemia/reperfusion, and ultimately to develop therapeutic strategies to improve hepatic function of patients with liver diseases.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Oct 2014
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 31, 2014
CompletedFirst Posted
Study publicly available on registry
April 3, 2014
CompletedStudy Start
First participant enrolled
October 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 6, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
June 6, 2019
CompletedSeptember 25, 2019
September 1, 2019
4.7 years
March 31, 2014
September 24, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Biochemical analysis of sirtuin1 from liver tissues during liver surgery
30 minutes during liver surgery
Study Arms (1)
Hepatocellular carcinoma
Participants undergoing a liver resection/liver transplantation surgery. During the liver surgery a small piece of tissue will be removed to undergo additional laboratory testing.
Interventions
Participants undergoing a liver resection/liver transplantation surgery. During the liver surgery a small piece of tissue will be removed to undergo additional laboratory testing.
Eligibility Criteria
Liver Disease Requring Liver Resection Surgery
You may qualify if:
- liver resection \> 2 segments,
- plate count \> 100 x 109/L, and
- prothrombin activity \>60%.
You may not qualify if:
- liver cirrhosis,
- portal hypertension,
- steatohepatitis or severe steatosis,
- patients receiving additional ablation therapies,
- laparoscopic resection, and
- simultaneous extrahepatic procedures such as colorectal resection or pancreatoduodenectomy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
UF Health
Gainesville, Florida, 32610, United States
Biospecimen
liver tissues during liver surgery
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jae-Sung Kim, PhD
University of Florida
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 31, 2014
First Posted
April 3, 2014
Study Start
October 1, 2014
Primary Completion
June 6, 2019
Study Completion
June 6, 2019
Last Updated
September 25, 2019
Record last verified: 2019-09
Data Sharing
- IPD Sharing
- Will not share